Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioAtla, Inc.

http://bioatla.com

Latest From BioAtla, Inc.

Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88

Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan. 

Financing Business Strategies

Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week

Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m. 

Financing Growth

Finance Watch: BioAtla, Virios And Scopus Launch Latest US IPOs

Public Company Edition: Initial public offerings may take a holiday break, but 2020 already has been a remarkable year for IPOs in the US and China. Also, Arvinas led the latest follow-ons with a $400m offering followed by TG Therapeutics with a $275m stock sale.

Financing Business Strategies

Genmab Accelerates Priority Candidates, Ends Enapotamab Vedotin Development

Denmark’s biotech Genmab has dropped the AXL targeted antibody-drug conjugate, enapotamab vedotin from early clinical development, and is focusing its resources on other therapeutic programs.

Cancer Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
  • Other Names / Subsidiaries
    • BioAtla, LLC
    • Himalaya Therapeutics SEZC
UsernamePublicRestriction

Register